Skip to content

Study · Randomized controlled trial · n = 114 · 2016

6 results

The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.

de Lapertosa SB, Frechtel G, Hardy E, Sauque-Reyna L

Diabetes research and clinical practice8 Oct 2016Cited by 2 (Europe PMC)

PMID27776251 (opens in a new tab)DOI10.1016/j.diabres.2016.10.001 (opens in a new tab)PepBankPUB-27776251
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In Latin American patients with type 2 diabetes, major and minor hypoglycemia occurred less frequently with exenatide than insulin lispro.

    In plain wordsIn Latin American patients with diabetes, low blood sugar events occurred less frequently with exenatide than insulin lispro.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMajor and minor hypoglycemia events
    Study

    n = 114

    Comparator
    Insulin lispro
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Major and minor hypoglycemia
    40 events
    exenatide
    Major and minor hypoglycemia
    253 events
    insulin lispro

    Source sentences

    Summary
    Major and minor hypoglycemia occurred less frequently (40 vs. 253 events) with exenatide BID compared with insulin lispro.
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.
  2. 02HumanRandomized controlled trialSafety outcome

    In Latin American patients with type 2 diabetes, nausea occurred more frequently with exenatide than insulin lispro.

    In plain wordsIn Latin American patients with diabetes, nausea occurred more frequently with exenatide than insulin lispro.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea
    Study

    n = 114

    Comparator
    Insulin lispro
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events of nausea, diarrhea, and vomiting occurred more frequently with exenatide BID than with insulin lispro.
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.
  3. 03HumanRandomized controlled trialSafety outcome

    In Latin American patients with type 2 diabetes, diarrhea occurred more frequently with exenatide than insulin lispro.

    In plain wordsIn Latin American patients with diabetes, diarrhea occurred more frequently with exenatide than insulin lispro.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiarrhea
    Study

    n = 114

    Comparator
    Insulin lispro
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events of nausea, diarrhea, and vomiting occurred more frequently with exenatide BID than with insulin lispro.
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.
  4. 04HumanRandomized controlled trialSafety outcome

    In Latin American patients with type 2 diabetes, vomiting occurred more frequently with exenatide than insulin lispro.

    In plain wordsIn Latin American patients with diabetes, vomiting occurred more frequently with exenatide than insulin lispro.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseVomiting
    Study

    n = 114

    Comparator
    Insulin lispro
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events of nausea, diarrhea, and vomiting occurred more frequently with exenatide BID than with insulin lispro.
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Latin American patients with type 2 diabetes, exenatide added to basal insulin reduced HbA1c by 0.9% from baseline.

    In plain wordsIn Latin American patients with diabetes, exenatide added to basal insulin lowered HbA1c by 0.9% from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.9%
    exenatide

    Source sentences

    Summary
    After 30weeks, addition of exenatide BID or insulin lispro resulted in significant (P<0.0001) reductions in HbA1c (exenatide BID: -0.9% [-10mmol/mol]; insulin lispro: -1.2% [-13mmol/mol]).
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Latin American patients with type 2 diabetes, weight remained stable with exenatide added to basal insulin.

    In plain wordsIn Latin American patients with diabetes, weight remained stable during exenatide treatment compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBody weight change
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Weight change
    −0.1 kg
    exenatide

    Source sentences

    Summary
    Weight was stable in the exenatide BID group (-0.1kg) and increased significantly (+3.4kg; P<0.0001) with insulin lispro.
    2 context sentences
    Summary · context
    This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114).
    Summary · context
    Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.